Impulse control disorder and associated clinical factors in drug-naïve Parkinson’s disease.
Objective: To investigate various clinical factors associated with Impulse Control Disorders (ICD) in Parkinson's disease (PD) patients who have never been exposed to Dopamine Replacement…Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment
Objective: The TOLEDO Study (NCT02006121) is a prospective, randomized, multicenter, double-blind, Phase III trial undertaken to investigate the efficacy of apomorphine subcutaneous infusion (APO) compared…An association between impulse control disorders and dopamine agonists in Japanese patients with Parkinson’s disease.
Objective: To evaluate an association between impulse control disorders (ICDs) and dopamine agonists (DA) therapy in Japanese patients with Parkinson’s disease (PD). Background: ICDs such…Efficacy of rotigotine as measured by individual Unified Parkinson’s Disease Rating Scale II and III items: a post-hoc analysis
Objective: The key aim was to assess the efficacy of rotigotine (RTG) transdermal patch on individual items of Unified Parkinson’s Disease Rating Scale (UPDRS) II…Genetic susceptibility associated to impulse control disorders and compulsive behaviors in Parkinson’s disease from a Spanish population.
Objective: Our aim was to identify if there is any difference in the genetic variants linked to an increased susceptibility to suffer impulse control disorders…Observational study of the effectiveness and tolerability of rotigotine+levodopa therapy in older vs younger Parkinson’s disease patients
Objective: Prospective non-interventional study conducted in routine clinical practice (PD0013; NCT02227355) to compare effectiveness and tolerability of rotigotine+levodopa (RTG+Ldopa) in Parkinson’s disease (PD) patients aged…Alien Limb Syndrome Induced by a Dopamine Agonist in a Patient with Parkinsonism and Agenesis of the Corpus Callosum
Objective: To examine the case of a patient with parkinsonism and agenesis of the corpus callosum whose alien limb phenomenology ceased after withdrawal from ropinirole.…Evaluation of rotigotine transdermal patch in combination with low or high dose levodopa in patients with Parkinson’s disease: post-hoc analysis
Objective: To investigate the value of adding the dopamine agonist (DA) rotigotine (RTG) to low (<400mg/day) or high (≥400mg/day) levodopa (Ldopa) doses in patients with…Driving license and car accidents in patients with Parkinson’s disease
Objective: To determine the incidence of and risk factors for car accidents in drivers with Parkinson’s disease (PD). Background: Few studies have addressed traffic accident…Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation
Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 15
- Next Page »